Loading clinical trials...

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

NCT05692596•H. Lee Moffitt Cancer Center and Research Institute

View on ClinicalTrials.gov

Summary

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•18 years of age or older
•Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
•Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
•Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

Locations (1)

Moffitt Cancer Center

Tampa, Florida, United States

Key Dates

Start Date

October 6, 2022

Primary Completion Date

July 1, 2026

Completion Date

July 1, 2026

Last Updated

January 8, 2026

Enrollment

317

ESTIMATED participants

Conditions

Pancreatic Ductal AdenocarcinomaPancreatic CystChronic PancreatitisFatty PancreasGenetic Pancreatic CancerGenetic PancreatitisBRCA MutationLynch SyndromeFAPFamilial Atypical Multiple Mole-MelanomaPALB2 Gene MutationPeutz-Jeghers SyndromeAtaxia Telangiectasia

Interventions

Data collection

OTHER

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Advanced CancerMetastatic Cancer+7 more

View study

RECRUITINGPHASE1/PHASE2

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062

Colorectal CancerCRC+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Inclusion Criteria

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors